RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal

1. RayzeBio Warned of Supply Issues: RayzeBio warned investors about potential actinium isotope supply issues before its $4.1 billion deal with Bristol Myers Squibb (BMS).
2. Actinium-225 Shortage: The company is currently facing a shortage of actinium-225, which is used in its lead radiotherapy candidate, RYZ101, to treat neuroendocrine tumors.
3. Supply Chain Challenges: RayzeBio relies on a Russian supplier for actinium, which poses risks due to geopolitical tensions.
4. BMS Acquisition: BMS acquired RayzeBio for $4.1 billion, highlighting the growing interest in radiopharmaceuticals.
5. Radiopharmaceuticals: Radiopharmaceuticals are becoming increasingly important in oncology, with companies like Novartis and Eli Lilly also investing in the field.
6. Manufacturing Capabilities: RayzeBio is building a 63,000-square-foot manufacturing facility in Indianapolis to produce actinium-225, which is critical for its radiopharmaceutical platform.
7. Clinical Trials: The company has temporarily halted new patient enrollment in its ACTION-1 phase 3 study due to the isotope shortage but plans to resume enrollment in the third quarter.